post modestli better ep result mark solid us pharmaci
perform despit on-going reimbursement/gener headwind
challeng retail environ strateg partnership remain focu
meaning expans lh collabor sever new partnership
continu progress it/suppli chain invest digit
initi cf remain robust integr track
environ remain challeng on-going degrad gross margin
bear watch maintain hold move pt ep
modest ep revenu came estim
in-lin perform pharmaci usa busi
off-set weak wholesal script volum
came bit estim better expect
rev/script drove in-lin result tie increas specialti volum brand
inflat continu market share gain despit solid yoy growth
tie store retail busi saw anoth declin
ss sale challeng consum gener merchandis
off-set strength health beauti divis better expect sg
sale vs strhe help off-set meaning gross
margin pressur anticip vs strhe drive
oper margin bp ep came three
cent ahead lower tax rate share count
conjunct earn walgreen labcorp lh buy
announc major expans current partnership agreement
open least labcorp patient servic center walgreen store
next four year includ exist locat addit compani
pursu avenu collabor increas patienc conveni
facilit consumpt servic also announc new
collabor kr birchbox privat
well expans collabor nr
sprint nr final make progress implement
new retail suppli chain pharmaci system expect
drive increas effici higher standard time
tr target
integr track integr store nr includ store
convers rebrand pilot make progress line optim plan
close store expect program complet end addit cost
integr optim initi in-lin expect compani
expect annual benefit tune step origin estim
cash flow strong cffo come solidli ahead
estim tie on-going w/c improv addit compani repurchas
share expect complet anoth buy-back manag
also provid initi ep guidanc growth vs strhe
consensu rais full year ep estim
tie aggress share repurchas activ lower assum share
retail pharmaci wholesal detail retail pharmaci revenu
came estim top line weak tie lower prescript
volum declin uk fund constant currenc basi ss pharmaci sale fell ss
retail sale fell total sale cc pharmaci wholesal revenu
touch despit strength emerg market ss sale increas cc
page
revenu
revenu
revenu
net incom
non-gaap add back tax
adjust net incom
page
inc global leader pharmaceut servic industri
store prior pend deal sizabl wholesale/distribut network countri
compani largest retail pharmaci unit state retail pharmaci usa divis
gener total compani revenu remain sale come
retail intern pharmaci wholesal
bullish underli trend pharmaceut servic expect sever tailwind
age popul util growth increas gener penetr growth specialti drive on-going
growth sector forese futur believ recent format sever strateg
partnership optum prime tricar demonstr valu compani scale/cap
provid near term volum tailwind reason optim challeng exist
 retail pharmaci busi continu see margin pressur tie sever factor
rate price pressur payer contract increasingli difficult overal retail environ
valuat risk
hold rate price target base stock trade adjust cash
ep slight discount current multipl upbeat underli trend
pharmaceut servic view compani scale key differenti upbeat
deal like compani free cash flow gener view risk/reward balanc given us
pharmaci margin pressur like linger difficult retail environ upsid risk
price target includ better synergi captur stronger core trend dissip pbm margin pressur
aggress capit deploy downsid risk includ issu integr increas
price pressur addit retail competit
compani mention note
laboratori corpor america hold lh buy david macdonald
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
